ReviewTaiwan journal of ophthalmology
Rod metabolic demand drives progression in retinopathies.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A mutation inMolecular vision · 2026Article
- CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa.Cell reports. Medicine · 2024Article
- Spatiotemporal control of genome engineering in cone photoreceptors.Cell & bioscience · 2023Article
- Gene-agnostic therapeutic approaches for inherited retinal degenerations.Frontiers in molecular neuroscience · 2022Review
- Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).American journal of ophthalmology case reports · 2021Article
- Macular thickness analysis and resolution of subretinal drusenoid deposits with optical coherence tomography in vitamin A deficiency-related retinopathy.American journal of ophthalmology case reports · 2021Article
- Low-oxygen and knock-out serum maintain stemness in human retinal progenitor cells.Molecular biology reports · 2020Article
- Perspectives on Gene Therapy: Choroideremia Represents a Challenging Model for the Treatment of Other Inherited Retinal Degenerations.Translational vision science & technology · 2020Article
- Hypoxic drive caused type 3 neovascularization in a preclinical model of exudative age-related macular degeneration.Human molecular genetics · 2019Article
- Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2018Article
- Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration.The Journal of clinical investigation · 2016Article
- BEST1: the Best Target for Gene and Cell Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various factors are thought to cause the development and progression of disease in macular degeneration, diabetic retinopathy, and retinitis pigmentosa. Some of the deleterious processes include oxidative stress, hypoxia, metabolic derangement, genetics, and vasculopathy. In this review, we present a unified theory for the pathophysiology of several retinopathies based on the unique and intense metabolism of rod photoreceptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.